XML 57 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1
SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Sep. 29, 2021
Dec. 18, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2013
Average interest rate, short-term bank deposits in U.S. dollars     0.77% 1.01%    
Amortization in R&D expenses     $ 1,291 $ 829 $ 627  
Revenue recognition under milestone method $ 6,000 $ 2,000        
Severance expenses     383 $ 572 $ 366  
Investment amount     12,000      
Upfront payment received     10,000     $ 10,000
Potential milestone compensation     200,000     $ 250,000
Accrued milestone payment     $ 8,000      
Options [Member]            
Weighted average number of shares related to outstanding options excluded from the calculations of diluted net loss per share     6,758,300 7,150,648 12,754,803  
Master Clinical Agreement One [Member]            
Investment amount     $ 12,000      
Deferred participation of BMS in R&D expenses     4,121      
Master Clinical Agreement Two [Member]            
Investment amount     20,000      
Deferred participation of BMS in R&D expenses     $ 5,000